Francica Joseph R, Shi Wei, Chuang Gwo-Yu, Chen Steven J, Da Silva Pereira Lais, Farney S Katie, Flynn Barbara J, Ou Li, Stephens Tyler, Tsybovsky Yaroslav, Wang Lawrence T, Anderson Alexander, Beck Zoltan, Dillon Marlon, Idris Azza H, Hurlburt Nicholas, Liu Tracy, Zhang Baoshan, Alving Carl R, Matyas Gary R, Pancera Marie, Mascola John R, Kwong Peter D, Seder Robert A
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21701, USA.
Vaccines (Basel). 2021 Mar 18;9(3):272. doi: 10.3390/vaccines9030272.
The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that are not included in RTS,S. Due to the fact that these antibodies protect against malaria challenge in mice, their epitopes could be effective vaccine targets. Here, we developed immunogens displaying PfCSP junctional epitopes by genetic fusion to either the N-terminus or B domain loop of the E2 protein from chikungunya (CHIK) alphavirus and produced CHIK virus-like particles (CHIK-VLPs). The structural integrity of these junctional-epitope-CHIK-VLP immunogens was confirmed by negative-stain electron microscopy. Immunization of these CHIK-VLP immunogens reduced parasite liver load by up to 95% in a mouse model of malaria infection and elicited better protection than when displayed on keyhole limpet hemocyanin, a commonly used immunogenic carrier. Protection correlated with PfCSP serum titer. Of note, different junctional sequences elicited qualitatively different reactivities to overlapping PfCSP peptides. Overall, these results show that the junctional epitopes of PfCSP can induce protective responses when displayed on CHIK-VLP immunogens and provide a basis for the development of a next generation malaria vaccine to expand the breadth of anti-PfCSP immunity.
最先进的疟疾疫苗RTS,S包含环子孢子蛋白(PfCSP)的中央重复序列和C末端结构域。我们最近分离出了靶向RTS,S中未包含的N末端和重复结构域之间连接区域的人类抗体。由于这些抗体能保护小鼠免受疟疾攻击,它们的表位可能是有效的疫苗靶点。在此,我们通过基因融合将PfCSP连接表位与基孔肯雅热(CHIK)甲病毒E2蛋白的N末端或B结构域环相连,开发了展示PfCSP连接表位的免疫原,并制备了CHIK病毒样颗粒(CHIK-VLPs)。通过负染色电子显微镜确认了这些连接表位-CHIK-VLP免疫原的结构完整性。在疟疾感染小鼠模型中,用这些CHIK-VLP免疫原进行免疫可使寄生虫肝脏负荷降低多达95%,并且与展示在常用免疫载体钥孔血蓝蛋白上相比,能引发更好的保护作用。保护作用与PfCSP血清滴度相关。值得注意的是,不同的连接序列对重叠的PfCSP肽产生了质的不同的反应性。总体而言,这些结果表明,PfCSP的连接表位在展示于CHIK-VLP免疫原上时可诱导保护性反应,并为开发下一代疟疾疫苗以扩大抗PfCSP免疫的广度提供了基础。